Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Lugano, Switzerland and San Diego, USA, 2 August, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products…